GlassScriptPhysician profile
Ramu P Raju
NPI 1275732984
$11,165.94
in general payments reported to CMS, 2019-2025
32 companies · $1,439 in 2025
The $1,439 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $857 · 2020: $634 · 2021: $973 · 2022: $1,389 · 2023: $1,449 · 2024: $4,426 · 2025: $1,439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,166 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,763 · Grant: $335 · Education: $49.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,165.99 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,762.50 |
| Grant | $335.00 |
| Education | $49.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,550.68 | 2021-2024 | Gi Genius, Bravo, Pillcam |
| Abbvie INC. | $2,398.28 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $848.68 | 2019-2024 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $683.08 | 2019-2024 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $662.96 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Boston Scientific Corporation | $447.18 | 2019-2024 | Exalt Model D, Spyglass |
| Regeneron Healthcare Solutions, INC. | $445.40 | 2022-2025 | Dupixent |
| Genzyme Corporation | $338.28 | 2022-2025 | |
| Celgene Corporation | $250.40 | 2021-2023 | Zeposia |
| Gilead Sciences, INC. | $219.36 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $182.35 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $144.55 | 2022-2024 | Ibsrela |
| Qol Medical, LLC | $140.69 | 2019-2025 | Sucraid |
| Lilly USA, LLC | $139.04 | 2024-2025 | Omvoh |
| Pfizer INC. | $118.44 | 2019-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $90.43 | 2024-2025 | Zenpep |
| Ipsen Biopharmaceuticals, INC | $73.81 | 2024-2025 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $64.15 | 2021-2023 | |
| Celltrion USA INC. | $47.51 | 2025 | Vegzelma |
| Allergan, INC. | $37.17 | 2019-2020 | |
| Ucb, INC. | $35.15 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $34.03 | 2022-2024 | |
| Ferring Pharmaceuticals INC. | $33.78 | 2023 | Rebyota |
| Echosens North America, INC. | $32.23 | 2024 | Fibroscan |
| Merck Sharp & Dohme LLC | $25.72 | 2019-2020 | |
| Conmed Corporation | $24.52 | 2025 | Conmed Biliary |
| Braintree Laboratories, INC. | $19.25 | 2025 | Suflave |
| Ironwood Pharmaceuticals, INC | $18.90 | 2019 | |
| Daiichi Sankyo INC. | $17.70 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.31 | 2025 | Austedo Xr |
| Shield Therapeutics INC | $14.93 | 2023 | Accrufer |
| Shionogi INC | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramu Raju listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.